(Q37394443)

20 August 2017

1 reference

title

What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? (English)

1 reference

20 August 2017

1 reference

1 reference

C H Barrios

1

1 reference

20 August 2017

C Sampaio

series ordinal

2

1 reference

20 August 2017

J Vinholes

series ordinal

3

1 reference

20 August 2017

R Caponero

series ordinal

4

1 reference

20 August 2017

language of work or name

1 reference

16 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

20

1 reference

20 August 2017

7

1 reference

20 August 2017

1157-1162

1 reference

Estrogen and the risk of breast cancer

20 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

The role of chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Hormonal therapy for postmenopausal breast cancer: the science of sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN756

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN756

1 reference

20 August 2017

1 reference